StreetAlpha.app
Home › Stocks › BCAX

Bicara Therapeutics Inc. (BCAX)

Healthcare
$9.60
▼ −1.54%
LAST CLOSE · NOV 17

Bicara Therapeutics develops ficerafusp alfa, an investigational antibody therapy for solid tumors such as head and neck cancers. It last closed at $9.60 on Nov 17, down 1.54% on the day. The average 12-month price target from 6 analysts is $29.67 (+209.0% from the last close), with a high of $43.00 and a low of $8.00. Analyst consensus is Buy, based on the latest ratings from 6 firms (5 buy, 0 hold, 1 sell). In the past 30 days there were 2 dark pool prints totaling $1.1M, the largest $667K.

AI Auto Pilots
Is BCAX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$220.3M
EPS (diluted)
−$3.46
−164.3% vs a year ago
Free cash flow
−$162.8M
Valuation
Market cap
$637.3M
66.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$82.0M
At Sep 30
Shareholder equity
$409.4M
Shares outstanding
66.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$52.0M−$52.0MFY2023FY2024: −$68.0M−$68.0MFY2024FY2025: −$137.9M−$137.9MFY2025

From BCAX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
6firms
5 Buy0 Hold1 Sell
Each firm's latest rating on BCAX in the past 90 days
Average 12-month target
$29.67
▲ 209.0% upside

Based on 6 analysts who set a price target on BCAX in the past 90 days. The average target is $29.67, with a high of $43.00 and a low of $8.00, compared with the last close of $9.60.

Low $8.00Avg $29.67High $43.00
Blue marker: last close $9.60
Highest target$43.00
Average target$29.67
Lowest target$8.00
Latest rating changes
HC Wainwright & Co.Maintained
Nov 11Buy$36
Morgan StanleyTarget lowered
Nov 10Buy$39 → $30
StifelMaintained
Nov 10Buy$43
BTIGTarget lowered
Nov 10Buy$39 → $37
Goldman SachsDowngrade
Oct 30Sell$20 → $8
DateFirmActionRatingPrice target
Nov 11HC Wainwright & Co.MaintainedBuy$36
Nov 10Morgan StanleyTarget loweredBuy$39 → $30
Nov 10StifelMaintainedBuy$43
Nov 10BTIGTarget loweredBuy$39 → $37
Oct 30Goldman SachsDowngradeSell$20 → $8
Loading…

Technical Analysis

BCAX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 19% below its 20 day and 70% below its 50 day average. It is 116% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 33), near oversold. The nearest support is the Pivot S1 at $9.34, and the nearest resistance the Pivot R1 at $9.85.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 11.8%/day
Key levels
$30.9952 week high+222.8%
$21.33100 day average+122.2%
$20.76200 day average+116.3%
$16.2950 day average+69.7%
$11.4220 day average+19.0%
$11.42Swing high (Nov 11)+19.0%
$9.85Pivot R1+2.6%
$9.60Pivot+0.0%
$9.60Last close
$9.34Pivot S1−2.7%
$7.8752 week low−18.0%
$7.87Swing low (Nov 2)−18.0%
Indicators
RSI (14)32.61Weak, oversold below 30Neutral
MACD-2.04Above its signal lineBullish
Stochastic30.1Middle of its rangeNeutral
ADX (14)48.4Strong downtrend
Williams %R-51.3Oversold below −80, overbought above −20Neutral
CCI (20)-43.1Oversold below −100, overbought above 100Neutral
Rate of change+7.1%Change over 10 sessionsBullish
ATR (14)$1.14Typical daily range, 11.8% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BCAX

What happened before

See how BCAX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in BCAX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.1M
Largest print
$667K
Loading…

BCAX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲95 buying vs 67 selling
  • ▼Held by funds -0.8 pts
  • ▼Funds holding -3
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding169172−1.7%
In funds' top 1059−44.4%
Held by funds104.3%105.1%−0.8 pts
New / increased25 / 7036 / 68−8.7%
Reduced / sold out40 / 2738 / 11+36.7%
Put/call ratio0.191.00−81.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BCAX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCAX is in one of them and how their past BCAX trades turned out.

BCAX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BCAX in an article yet. Here's the latest on the wider market.

About Bicara Therapeutics

Bicara Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that is developing treatments for solid tumors. Its main candidate, ficerafusp alfa, is an investigational antibody that pairs an antibody targeting the EGFR protein on tumor cells with a molecule that blocks TGF-β, a signaling protein that helps tumors resist treatment. The candidate is being tested mainly in head and neck squamous cell carcinoma, and the company does not yet sell a product. Its intended patients are people with solid tumors, starting with head and neck cancers.

Headquarters
Boston, MA